Recombinant Antibodies for Immunotherapy (eBook, ePUB)

Redaktion: Little, Melvyn

• Format: ePub

Produktbeschreibung

Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, 'arming' mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field, biology and biotechnology students, research and development departments in the pharmaceutical industry, medical researchers, clinicians, and biotechnology investors.

---

Dieser Download kann aus rechtlichen Gründen nur mit Rechnungsadresse in A, B, BG, CY, CZ, D, DK, EW, E, FIN, F, GR, HR, H, IRL, I, LT, L, LR, M, NL, PL, P, R, S, SLO, SK ausgeliefert werden.

Produktdetails

• Verlag: Cambridge University Press
• Erscheinungstermin: 27. Juli 2009
• Englisch
• ISBN-13: 9780511698927
• Artikelnr.: 37834254

Inhaltsangabe

Part I. Introduction: 1. Past, present and future of recombinant antibodies
G. Winter; Part II. Generation and Screening of Antibody Libraries: 2.
Antibody libraries from naïve V gene sources G. Beste and D. Lowe; 3.
Antibodies from IgM libraries V. Molkenthin and S. Knackmuss; Part III.
Transgenic Human Antibody Repertoires: 4. The generation and screening of
synthetic antibody libraries I. Klagge; 5. Therapeutic antibodies from
xenoMouse transgenic mice A. Jakobovits; 6. Transgenic chimeric antibodies
A. Murphy; Part IV. Humanised Antibodies: 7. Humanization of recombinant
antibodies J. Saldanha; 8. Immunogenicity assessment of antibody
therapeutics P. Stas, J. Pletinckx, Y. Gansemans, and I. Lasters; 9. In
vitro screening for antibody immunogenicity F. Carr and M. Baker; Part V.
Antibody Effector Function: 10. Mechanisms of tumour cell killing by
therapeutic antibodies R. Stewart and C. Webster; 11. Optimization of Fc
domains to enhance antibody therapeutics G. Lazar and A. Chamberlain; 12.
Glycoengineered therapeutic antibodies P. Brünker, P. Sondermann, and P.
Umana; Part VI. Arming Antibodies: 13. Monoclonal antibodies for the
delivery of cytotoxic drugs D. King; 14. Immunotherapy with radioimmune
conjugates C. Kousparou and A. Epenetos; 15. Immunotherapeutic antibody
fusion proteins N. Courtenay-Luck and D. Jones; Part VII. Antibody
Fragments: 16. Alternative antibody formats F. Le Gall and M. Little; 17.
Single domain antibodies S. Muyldermans; 18. Engineering of non-CDR loops
in immunoglobulin domains F. Rüker and G. Wozniak-Knopp; Part VIII. Antigen
Binding Repertoires of Non-Immunoglobulin Proteins: 19. Alternative
antibody scaffolds A. Plueckthun; Part IX. Prolongation of Serum Half Life:
20. Polymer fusions to increase antibody half lives: PEGylation and other
modifications S. Heywood and D. Humphreys; 21. Extending antibody
half-lives with albumin J. Andersen and I. Sandlie; Part X. Current
Therapeutic Antibodies and Novel Developments: 22. A stem cell-based
platform for the discovery and development of anti-tumor therapeutic
antibodies to novel targets J. Mather, C. Fieger, T. Liang, K. King, J. Li,
P. Young, C. Beltejar, B. Potts, M. Licea, and D. Loo; 23. Antibody
directed enzyme prodrug therapy (ADEPT) H. Lowe, S. Sharma, and K.
Bagshawe; 24. Immune privilege and tolerance - therapeutic antibody
approaches D. Forman, P. Ponath, D. Mehta, J. Ponte, J. Snyder, P. Rao, H.
Waldmann, and M. Rosenzweig; Part XI. Market Overview and Outlook: 25.
Antibody therapeutics: business achievements and business outlook C.
Bourrilly.